A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

August 31, 2006

Study Completion Date

November 30, 2006

Conditions
Rectal Cancer
Interventions
DRUG

Capecitabine

Capecitabine is available as 50 mg and 500 mg tablets. It will be administered as a 1000mg/m\^2 bid orally on Days 1-14, and at a dose of 825mg/m\^2 bid on Days 22-35 and 43-56.

DRUG

Oxaliplatin

Oxaliplatin is available in vials containing 50 mg or 100 mg. It will be administered as a oxaliplatin 130mg/m\^2/d intravenously on Day 1 and 50mg/m\^2/d on Days 22, 29, 43 and 50 prior to radiotherapy up to Week 9 followed by surgery period.

Trial Locations (6)

4031

Basel

6004

Lucerne

7000

Chur

8037

Zurich

8063

Zurich

9007

Sankt Gallen

All Listed Sponsors
collaborator

Sanofi-Synthélabo (Schweiz) AG

UNKNOWN

lead

Hoffmann-La Roche

INDUSTRY

NCT02694718 - A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer | Biotech Hunter | Biotech Hunter